Spiriva (tiotropium bromide) is a prescription drug that’s used to treat COPD and asthma. The drug comes in an inhaler. It’s usually used once per day. Spiriva is a prescription drug that comes in two ...

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...

Tiotropium (as bromide monohydrate) 18mcg/cap; dry pwd in caps for oral inhalation; with inhaler device. Spiriva Handihaler consists of Spiriva capsules and the Handihaler device. Spiriva capsules ...

Spiriva (tiotropium) is a prescription drug used to treat specific breathing conditions. Spiriva’s cost may depend on factors such as your dosage, whether you have health insurance, and the pharmacy ...

Want to know what asthma feels like? Try a crushing bear hug. That’s what patients told Boehringer Ingelheim, informing its latest campaign for Spiriva Respimat as a treatment for asthma. In new TV ...

Spiriva, a drug that is already widely used to treat chronic obstructive pulmonary disease, can provide significant relief of symptoms for adult asthmatics who have difficulty obtaining relief with ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- ...

Lupin has received the Food and Drug Administration’s permission for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic of Boehringer Ingelheim’s Spiriva HandiHaler. The ...

Lannett has entered into an exclusive U.S. commercialization agreement for generic Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals. The 10-year term of the ...

Federal health regulators said Thursday that recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death. The Spiriva HandiHaler is ...

A Spiriva-based combination therapy that Boehringer Ingelheim believes will consolidate its position in the chronic obstructive pulmonary disease (COPD) market has been cleared for marketing in nine ...

In laying out their respective plans Monday to launch new direct-to-patient (DTP) platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in ...